BioWorld

March 4, 2004

Biogen Idec Earnings Lower Than Wall Street's Forecast

Reporting for the first time as a combined entity, Biogen Idec Inc. missed consensus earnings estimates by 8 cents, posting pro forma earnings per share of 24 cents for the fourth quarter. Its full-year adjusted EPS totaled $1.22. (BioWorld Today) Read More

Isis Awarded $19.5M Government Contract For Biowarfare Product

Harvard Scientist Generates 17 Additional Stem Cell Lines

Nuvelo Raises Share Amount, Gets $65M In Public Offering

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...